Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041).
Choi MC, Kim YM, Lee JW, Lee YJ, Suh DH, Lee SJ, Lee TS, Lee M, Park DC, Kim MK, Lee JM, Shim SH, Jeon S, Min KJ, Kim MK, Kim BW, Park JY, Kim BG, Kim DY, Kim MH, Kim HS, Lee JY. Choi MC, et al. Cancers (Basel). 2020 Oct 29;12(11):3188. doi: 10.3390/cancers12113188. Cancers (Basel). 2020. PMID: 33138190 Free PMC article.
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Lee JY, Park JY, Park SY, Lee JW, Kim JW, Kim YB, Jeong DH, Lee KB, Kim TH, Lee IH, Choi MC, Kim KH, Kim YM, Lee YJ, Kang S; KGOG Investigators; Pujade-Lauraine E. Lee JY, et al. Among authors: choi mc. Gynecol Oncol. 2019 Jan;152(1):61-67. doi: 10.1016/j.ygyno.2018.10.031. Epub 2018 Nov 6. Gynecol Oncol. 2019. PMID: 30409490
Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
Chung YS, Park SY, Lee JY, Park JY, Lee JW, Kim HS, Suh DS, Kim YH, Lee JM, Kim M, Choi MC, Shim SH, Lee KH, Song T, Hong JH, Lee WM, Lee B, Lee IH. Chung YS, et al. Among authors: choi mc. BMC Cancer. 2019 Apr 11;19(1):341. doi: 10.1186/s12885-019-5514-7. BMC Cancer. 2019. PMID: 30971221 Free PMC article.
Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
Choi MC, Chung YS, Lee JW, Kwon BS, Park BK, Kim SI, Shim SH, Lee KB, Seong SJ, Lee SJ, Lee SH, Yoo HJ, Song T, Kim MK, Baek MH, Kang S, Kim YM. Choi MC, et al. Eur J Cancer. 2020 Jul;133:56-65. doi: 10.1016/j.ejca.2020.03.030. Epub 2020 May 19. Eur J Cancer. 2020. PMID: 32442924
Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).
Kim SI, Lee JW, Kim K, Lee M, Yoo J, Choi MC, Hwangbo S, Kwak YH, Lee JM, Shin SJ, Shim SH, Kim MK. Kim SI, et al. Among authors: choi mc. J Gynecol Oncol. 2021 Nov;32(6):e90. doi: 10.3802/jgo.2021.32.e90. Epub 2021 Aug 5. J Gynecol Oncol. 2021. PMID: 34431258 Free PMC article.
228 results